Lisata Therapeutics Announces Participation in Upcoming Conferences in September
2023年9月5日 - 9:00PM
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the
“Company”), a clinical-stage pharmaceutical company developing
innovative therapies for the treatment of advanced solid tumors and
other serious diseases, today announced that David J. Mazzo, PhD,
Chief Executive Officer of Lisata, will present at two upcoming
conferences in September. Details of the events are as follows:
H.C.
Wainwright 25th
Annual Global Investment Conference
September 11-13 | New York City, NY
Dr. Mazzo’s presentation will be available on-demand on
September 11, 2023, at 7:00 a.m. Eastern Time. Management will also
participate in one-on-one meetings with investors on September
11th. For more information about the H.C. Wainwright 25th Annual
Global Investment Conference, please visit
https://hcwevents.com/annualconference/#toggle-id-5.
LSX World Congress USA
September 13-14 | Boston, MA
Dr. Mazzo will deliver a live presentation on Thursday,
September 14, 2023, at 11:00 a.m. Eastern Time. Management will
also participate in one-on-one meetings with investors on September
14th. For more information about the LSX World Congress USA, please
visit https://www.lsxleaders.com/lsx-usa-congress.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company
dedicated to the discovery, development and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s lead product candidate, LSTA1, is an
investigational drug designed to activate a novel uptake pathway
that allows co-administered or tethered anti-cancer drugs to target
and penetrate solid tumors more effectively. Based on Lisata’s
CendR Platform® Technology, Lisata has already established
noteworthy commercial and R&D partnerships. The Company expects
to announce numerous clinical study and business milestones over
the next two years and has projected that its current business and
development plan is funded with available capital through these
milestones and into early 2026. For more information on the
Company, please visit www.lisata.com.
Contact:
Investors and Media:
Lisata Therapeutics, Inc.John MendittoVice President, Investor
Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Lisata Therapeutics (NASDAQ:LSTA)
過去 株価チャート
から 4 2024 まで 5 2024
Lisata Therapeutics (NASDAQ:LSTA)
過去 株価チャート
から 5 2023 まで 5 2024